Duravest

Duravest, Inc. was a publicly traded life sciences holding company that specialized in "convergent medical technologies," a field integrating biotechnology with medical devices. The company's primary focus during its peak operations in the mid-2000s was its majority stake in Estracure, Inc., a biopharmaceutical firm developing 17-beta-estradiol for the prevention of restenosis following coronary angioplasty. Historically, Duravest was also the developer of the DuraGen dural graft matrix, a significant neurosurgical product whose assets were acquired by Integra LifeSciences in 1999. The company aimed to leverage unique therapeutic properties, such as the dual mode of action of estrogen in cardiovascular repair, to improve clinical outcomes. Duravest was headquartered in Toronto and maintained listings on the OTC Bulletin Board and the Frankfurt Stock Exchange.